Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Wierda

Showing results (51-60 of 181) with videos related to

Pageof 19
Sort By:
Cancer|June 23, 2005
Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapyHagop M Kantarjian, Carlos E Bueso-Ramos, Moshe Talpaz, et al.
American Journal of Hematology|February 27, 2026
The Care and Cure of the Leukemias in 2026Hagop Kantarjian, Helen T Chifotides, Fadi G Haddad, et al.
International Journal of Molecular Sciences|March 29, 2023
Reverse Phase Protein Array Profiling Identifies Recurrent Protein Expression Patterns of DNA Damage-Related Proteins across Acute and Chronic Leukemia: Samples from Adults and the Children's Oncology GroupFieke W Hoff, Ti'ara L Griffen, Brandon D Brown, et al.
Blood|April 16, 2008
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemiaConstantine S Tam, Susan O'Brien, William Wierda, et al.
Cancer|September 16, 2003
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemiaJorge Cortes, Moshe Talpaz, Susan O'Brien, et al.
Cancer|May 12, 2006
Activity of alemtuzumab in patients with CD52-positive acute leukemiaRaoul Tibes, Michael J Keating, Alessandra Ferrajoli, et al.
Leukemia & Lymphoma|May 7, 2015
Analysis of class I and II histone deacetylase gene expression in human leukemiaHui Yang, Sirisha Maddipoti, Andres Quesada, et al.
American Journal of Hematology|February 17, 2015
High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcomePreetesh Jain, Michael Keating, Phillip A Thompson, et al.
Blood Cancer Journal|March 18, 2022
Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targetsTi'ara L Griffen, Fieke W Hoff, Yihua Qiu, et al.
Leukemia & Lymphoma|February 22, 2018
Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemiaUri Rozovski, David M Harris, Ping Li, et al.
Pageof 19

Showing results (51-60 of 181) with videos related to

Sort By:
Pageof 19
Cancer|June 23, 2005
Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapyHagop M Kantarjian, Carlos E Bueso-Ramos, Moshe Talpaz, et al.
American Journal of Hematology|February 27, 2026
The Care and Cure of the Leukemias in 2026Hagop Kantarjian, Helen T Chifotides, Fadi G Haddad, et al.
International Journal of Molecular Sciences|March 29, 2023
Reverse Phase Protein Array Profiling Identifies Recurrent Protein Expression Patterns of DNA Damage-Related Proteins across Acute and Chronic Leukemia: Samples from Adults and the Children's Oncology GroupFieke W Hoff, Ti'ara L Griffen, Brandon D Brown, et al.
Blood|April 16, 2008
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemiaConstantine S Tam, Susan O'Brien, William Wierda, et al.
Cancer|September 16, 2003
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemiaJorge Cortes, Moshe Talpaz, Susan O'Brien, et al.
Cancer|May 12, 2006
Activity of alemtuzumab in patients with CD52-positive acute leukemiaRaoul Tibes, Michael J Keating, Alessandra Ferrajoli, et al.
Leukemia & Lymphoma|May 7, 2015
Analysis of class I and II histone deacetylase gene expression in human leukemiaHui Yang, Sirisha Maddipoti, Andres Quesada, et al.
American Journal of Hematology|February 17, 2015
High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcomePreetesh Jain, Michael Keating, Phillip A Thompson, et al.
Blood Cancer Journal|March 18, 2022
Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targetsTi'ara L Griffen, Fieke W Hoff, Yihua Qiu, et al.
Leukemia & Lymphoma|February 22, 2018
Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemiaUri Rozovski, David M Harris, Ping Li, et al.
Pageof 19